Multiple studies have investigated the relationship between Androgenetic Alopecia and cardiovascular disease, including studies that have identified risks of cardiovascular disease in patients with vertex hair loss, vertex and frontal hair loss, early onset hair loss and rapidly progressive hair loss.
Studies investigating an association between Androgenetic Alopecia and metabolic syndrome have yielded conflicting findings. Distinct guidelines for the detection and prevention of cardiovascular disease in individuals with Androgenetic Alopecia have not yet been established.
In addition to the traditional risk factors for developing cardiovascular disease, included in the definition of the metabolic syndrome, several skin diseases have recently been shown to be markers of conditions relating to the patient’s overall health. Physicians should be aware of the possible connection between relatively frequent skin diseases, such as psoriasis and hair growth disruptions, including Androgenetic Alopecia and Female Pattern Hair Loss, and cardiovascular disease.
This review is concentrated on the association between insulin resistance, type 2 diabetes, abdominal fat, cardiovascular disease and hair growth disruptions as early indicators of these underlying health conditions. It investigates the importance of robust primary clinical treatment measures to address the manifestation of hair loss due to a disruption caused by, for example, metabolic syndrome as an effective means to alleviate further stress-induced hair loss, which can exacerbate the patient’s overall health profile.
It is essential that the treatment of hair loss, which could be associated with metabolic syndrome, is twofold; the treating physician should always consider whether any existing hair loss could be an indicator of metabolic syndrome – or any related conditions. Likewise, it is important to treat the hair loss on an equal footing with lifestyle related changes and treatments associated with any lifestyle diseases to prevent additional stress and cortisol-induced hair loss. Furthermore, when deciding on a treatment to address Androgenetic Alopecia and Female Pattern Hair Loss, it is vital to avoid interactions with any ongoing medical treatments.
Conclusion: A naturally based, side effect free Proteoglycan Replacement Therapy, Nourkrin® with Marilex®, has been shown to be an effective treatment for Anagen induction and prolongation. It is an efficacious treatment for hair loss associated with a number of medical conditions, including metabolic syndrome.
Read the article here: https://www.heighpubs.org/hjd/pdf/adr-aid1002.pdf